← All trials
NCT06660719
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2024
- Primary completion
- Mar 30, 2027
- Completion date
- Mar 30, 2027
- First posted
- Oct 28, 2024
- Last posted
- Oct 28, 2024
- Enrollment
- 852
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shin Poong PharmaceuticalsLead sponsor
- University of UlsanOfficial
- University of UlsanOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.